Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $24.25.

Several brokerages recently commented on XNCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. increased their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Truist Financial reduced their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th.

Xencor Stock Performance

XNCR stock opened at $17.47 on Monday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.63 and a beta of 0.86. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69. The firm has a 50-day moving average price of $13.21 and a 200-day moving average price of $12.77.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The company’s revenue for the quarter was down 86.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.66) earnings per share. As a group, equities analysts predict that Xencor will post -3.88 EPS for the current fiscal year.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently made changes to their positions in XNCR. ADAR1 Capital Management LLC increased its stake in shares of Xencor by 66.8% in the first quarter. ADAR1 Capital Management LLC now owns 93,665 shares of the biopharmaceutical company’s stock valued at $1,130,000 after buying an additional 37,500 shares during the period. Quantinno Capital Management LP boosted its position in Xencor by 21.1% during the 1st quarter. Quantinno Capital Management LP now owns 57,077 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 9,943 shares during the period. Dimensional Fund Advisors LP grew its holdings in Xencor by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after acquiring an additional 45,599 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Xencor by 2.0% during the 1st quarter. Principal Financial Group Inc. now owns 347,078 shares of the biopharmaceutical company’s stock worth $4,186,000 after acquiring an additional 6,752 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in Xencor by 3,690.2% in the 1st quarter. Fifth Third Bancorp now owns 17,018 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 16,569 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.